Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
Search
Trial Profile

Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZM-008 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; B-cell lymphoma; Biliary cancer; Colorectal cancer; Diffuse large B cell lymphoma; Glioma; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic ductal carcinoma; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Zumutor Biologics

    • Most Recent Events

    • 25 Oct 2024 Results assessing the safety tolerability, PK, immunogenicity and efficacy of ZM008 in advanced solid tumor subjects were presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
    • 12 Jun 2024 According to a Zumutor Biologics media release, The study will recommend the Phase 2 dose.
    • 12 Jun 2024 According to a Zumutor Biologics media release, the company announced that the first patient was dosed in its Phase 1 clinical trial, with ZM008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top